









Markets
/
Stocks
/
nasdaq-dcth
/

Delcath Systems Inc

DCTH

9.370USD

+0.430+4.81%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

330.84MMarket Cap

210.18P/E TTM



Delcath Systems Inc

9.370

+0.430+4.81%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Delcath Systems Inc

Currency: USD Updated: 2026-02-06

Key Insights

Delcath Systems Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 66 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.14.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Delcath Systems Inc's Score

Industry at a Glance

Industry Ranking

66 / 205

Overall Ranking

176 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Delcath Systems Inc Highlights

StrengthsRisks

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1268.33% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 37.20M.

Overvalued

The company’s latest PE is 210.18, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 18.04M shares, increasing 0.01% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.67M shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

23.143

Target Price

+158.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Delcath Systems Inc is 9.50, ranking 5 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 20.56M, representing a year-over-year increase of 83.60%, while its net profit experienced a year-over-year increase of 55.47%.

Score

Industry at a Glance

Previous score

9.50

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.80

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.68

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Delcath Systems Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Delcath Systems Inc is 4.70, ranking 189 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 210.18, which is 17.18% below the recent high of 246.30 and 119.22% above the recent low of -40.39.

Score

Industry at a Glance

Previous score

4.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 66/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Delcath Systems Inc is 8.57, ranking 22 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 22.00, with a high of 30.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.57

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

23.143

Target Price

+158.87%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Delcath Systems Inc

DCTH

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Delcath Systems Inc is 6.80, ranking 84 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 10.71 and the support level at 8.46, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.45

Change

0.35

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.274

Sell

RSI(14)

39.335

Neutral

STOCH(KDJ)(9,3,3)

18.769

Neutral

ATR(14)

0.464

High Vlolatility

CCI(14)

-148.026

Sell

Williams %R

79.111

Sell

TRIX(12,20)

-0.168

Sell

StochRSI(14)

60.465

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

9.592

Sell

MA10

9.846

Sell

MA20

10.125

Sell

MA50

10.047

Sell

MA100

10.125

Sell

MA200

11.487

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Delcath Systems Inc is 5.00, ranking 113 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 62.08%, representing a quarter-over-quarter decrease of 4.39%. The largest institutional shareholder is The Vanguard, holding a total of 1.67M shares, representing 4.74% of shares outstanding, with 18.31% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Rosalind Advisors, Inc.

3.30M

The Vanguard Group, Inc.

Star Investors

1.66M

+2.90%

BlackRock Institutional Trust Company, N.A.

1.59M

+2.00%

Simplify Asset Management Inc

699.63K

+110.30%

Geode Capital Management, L.L.C.

687.61K

-2.21%

Nantahala Capital Management, LLC

666.43K

State Street Investment Management (US)

621.25K

+31.09%

Vivo Capital, LLC

569.53K

Divisadero Street Capital Management, LP

476.16K

Citadel Advisors LLC

449.31K

-44.06%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Delcath Systems Inc is 5.04, ranking 90 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.37. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.